PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covid-19 solutions, such as PCLMD nCoV one step RT-PCR, PCL COVID19 speed RTPCR, PCLMD ABC multi RTPCR molecular diagnostic kits; PCL COVID19 Ag rapid FIA, and PCL COVID19 Ag gold antigen diagnostic kits; and PCL COVID19 IgG/IgM rapid gold, and PCL COVID19 total Ab EIA antibody diagnostic kits. PCL, Inc. was incorporated in 2008 and is headquartered in Seoul, South Korea.
Metrics to compare | 241820 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship241820PeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −7.1x | −0.5x | |
PEG Ratio | 0.00 | −0.14 | 0.00 | |
Price/Book | 2.6x | 1.8x | 2.6x | |
Price / LTM Sales | 6.3x | 3.7x | 3.1x | |
Upside (Analyst Target) | - | 58.1% | 45.7% | |
Fair Value Upside | Unlock | −2.1% | 5.7% | Unlock |